{"doc_id": "si-2022-0418-reg-1", "parent_doc_id": "si-2022-0418", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 418 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "1. These Regulations may be cited as the European Union (Clinical Trials", "text_raw": "1. These Regulations may be cited as the European Union (Clinical Trials \non Medicinal Products for Human Use) (Principal) (Amendment) Regulations", "text_norm": "1 regulation may cited european union (clinical trial medicinal product human use) (principal) (amendment) regulation", "start_char": 643, "end_char": 791, "source_path": "downloads\\2022\\2022_0417.pdf", "extraction_method": "pdfminer", "checksum": "sha256:090fdc4a1d3bedda9890fdb8aa78ecaa81c26ccedb4602f6716a2b23d9f91fb0", "cross_refs": []}
{"doc_id": "si-2022-0418-reg-2022", "parent_doc_id": "si-2022-0418", "section_id": "reg-2022", "section_label": "Regulation 2022.", "si_number": "S.I. No. 418 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": null, "text_raw": "2022.", "text_norm": "2022", "start_char": 791, "end_char": 799, "source_path": "downloads\\2022\\2022_0417.pdf", "extraction_method": "pdfminer", "checksum": "sha256:090fdc4a1d3bedda9890fdb8aa78ecaa81c26ccedb4602f6716a2b23d9f91fb0", "cross_refs": []}
{"doc_id": "si-2022-0418-reg-2", "parent_doc_id": "si-2022-0418", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 418 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "2. These Regulations shall be deemed to have come into operation on 02", "text_raw": "2. These Regulations shall be deemed to have come into operation on 02 \n\nMarch 2022.", "text_norm": "2 regulation shall deemed come operation 02 march 2022", "start_char": 799, "end_char": 886, "source_path": "downloads\\2022\\2022_0417.pdf", "extraction_method": "pdfminer", "checksum": "sha256:090fdc4a1d3bedda9890fdb8aa78ecaa81c26ccedb4602f6716a2b23d9f91fb0", "cross_refs": []}
{"doc_id": "si-2022-0418-reg-3", "parent_doc_id": "si-2022-0418", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 418 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "In these Regulations “Principal Regulations” means the European", "text_raw": "3. \n\nIn these Regulations “Principal Regulations” means the European \nUnion (Clinical Trials on Medicinal Products for Human Use) (Principal) \nRegulations 2022 (S.I. No. 99 of 2022).", "text_norm": "3 regulation principal regulation mean european union (clinical trial medicinal product human use) (principal) regulation 2022 (s.i no 99 2022)", "start_char": 886, "end_char": 1071, "source_path": "downloads\\2022\\2022_0417.pdf", "extraction_method": "pdfminer", "checksum": "sha256:090fdc4a1d3bedda9890fdb8aa78ecaa81c26ccedb4602f6716a2b23d9f91fb0", "cross_refs": []}
{"doc_id": "si-2022-0418-reg-4", "parent_doc_id": "si-2022-0418", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 418 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "4. Regulation 3(1) of the Principal Regulations is amended –", "text_raw": "4. Regulation 3(1) of the Principal Regulations is amended – \n\n(a) by substituting for the definition of “Clinical Trials Regulation” \n\nthe following: \n“‘Clinical Trials Regulation’ means Regulation (EU) No. \n536/2014 of the European Parliament and of the Council of 16 \nApril 20141 on clinical trials on medicinal products for human \nuse (as amended);”, \n\n(b) by substituting for the definition of “Directive” the following: \n\n“‘Directive’ means Directive 2001/20/EC of the European \nParliament and of the Council of 4 April 20014 (as amended);”, \nand \n\n(c) by substituting for the definition of “Directive 2001/83/EC” the \n\nfollowing: \n“‘Directive 2001/83/EC6 means Directive 2001/83/EC of the \nEuropean Parliament and of the Council (as amended);”.", "text_norm": "4 regulation 3(1) principal regulation amended - (a) substituting definition clinical trial regulation following clinical trial regulation mean regulation (eu) no 536 2014 european parliament council 16 april 20141 clinical trial medicinal product human use (as amended) (b) substituting definition directive following directive mean directive 2001 20 ec european parliament council 4 april 20014 (as amended) (c) substituting definition directive 2001 83 ec following directive 2001 83 ec6 mean directive 2001 83 ec european parliament council (as amended)", "start_char": 1071, "end_char": 1825, "source_path": "downloads\\2022\\2022_0417.pdf", "extraction_method": "pdfminer", "checksum": "sha256:090fdc4a1d3bedda9890fdb8aa78ecaa81c26ccedb4602f6716a2b23d9f91fb0", "cross_refs": []}
{"doc_id": "si-2022-0418-reg-5", "parent_doc_id": "si-2022-0418", "section_id": "reg-5", "section_label": "Regulation 5.", "si_number": "S.I. No. 418 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "5. The Principal Regulations are amended by substituting for Regulation", "text_raw": "5. The Principal Regulations are amended by substituting for Regulation \n\n28 the following: \n“28. (1) Subject to paragraph (2), in accordance with Article 61(1) of the \nClinical Trials Regulation, \nimportation of \ninvestigational medicinal products shall be subject to the holding of a \nmanufacturer’s authorisation. \n\nthe manufacturing and \n\n1 OJ No. L. 118, 20.04.2022, p.1. \n1 OJ No. L. 158, 27.5.2014, p. 1. \n4 O.J. No. L 121, 1.5.2001, p. 34. \n6 O.J. No. L 311, 28.11.2001, p. 67. \n\nNotice of the making of this Statutory Instrument was published in \n“Iris Oifigiúil” of 23rd August, 2022. \n\n \n \n \n \n \n \n \n \n \n \n\f[418] 3 \n\n(2) Until 31 December 2024, the import of investigational medicinal \nproducts from parts of the United Kingdom other than Northern Ireland shall \nnot be subject to the holding of a manufacturer’s authorisation provided that all \nof the following conditions are fulfilled – \n\n(a) \n\n(b) \n\ninvestigational medicinal products have undergone \nthe \ncertification of batch release either in the Union or in parts of \nthe United Kingdom other than Northern Ireland to verify \ncompliance with the requirements set out in Article 63(1) of the \nClinical Trials Regulation, and \nthe investigational medicinal products are only made available \nto subjects in the State.” \n\nGIVEN under the Official Seal of the Minister for Health, \n\n18 August, 2022. \n\nMUIRIS O'CONNOR, \n\nA person authorised under section 15 of the Ministers and \nSecretaries Act 1924 to authenticate the seal of the \nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n\f4 [418]", "text_norm": "5 principal regulation amended substituting regulation 28 following 28 (1) subject paragraph (2) accordance article 61(1) clinical trial regulation importation investigational medicinal product shall subject holding manufacturer authorisation manufacturing 1 oj no l 118 20.04.2022 p.1 1 oj no l 158 27.5.2014 p 1 4 o.j no l 121 1.5.2001 p 34 6 o.j no l 311 28.11.2001 p 67 notice making statutory instrument published iris oifigiuil 23rd august 2022 418 3 (2) 31 december 2024 import investigational medicinal product part united kingdom northern ireland shall subject holding manufacturer authorisation provided following condition fulfilled - (a) (b) investigational medicinal product undergone certification batch release either union part united kingdom northern ireland verify compliance requirement set article 63(1) clinical trial regulation investigational medicinal product made available subject state given official seal minister health 18 august 2022 muiris connor person authorised section 15 minister secretary act 1924 authenticate seal minister health 4 418", "start_char": 1825, "end_char": 3376, "source_path": "downloads\\2022\\2022_0417.pdf", "extraction_method": "pdfminer", "checksum": "sha256:090fdc4a1d3bedda9890fdb8aa78ecaa81c26ccedb4602f6716a2b23d9f91fb0", "cross_refs": []}
{"doc_id": "si-2022-0418-explanatory-note", "parent_doc_id": "si-2022-0418", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 418 of 2022", "title": "3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose", "year": 2022, "heading": "(This note is not part of the instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the instrument and does not purport to be a legal \ninterpretation) \n\nThe main purpose of these Regulations is to implement Article 1 of Regulation \n(EU) No. 2022/641 of 12 April 2022, which amends Regulation (EU) No \n536/2014 as regards a derogation from certain obligations concerning \ninvestigational medicinal products. \n\n \n \n \n \n \n \n \n\f[418] 5 \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€ 3.00 \n\n(DH-440) 75. 8/22. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation) main purpose regulation implement article 1 regulation (eu) no 2022 641 12 april 2022 amends regulation (eu) 536 2014 regard derogation certain obligation concerning investigational medicinal product 418 5 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur 3.00 (dh-440) 75 8 22 propylon", "start_char": 3376, "end_char": 4254, "source_path": "downloads\\2022\\2022_0417.pdf", "extraction_method": "pdfminer", "checksum": "sha256:090fdc4a1d3bedda9890fdb8aa78ecaa81c26ccedb4602f6716a2b23d9f91fb0", "cross_refs": []}
